Li et al. (2019) revealed that methylation-driver mRNA and lncRNA contributed to the survival of LUAD, and eight mRNAs and four lncRNAs might be candidate biomarkers. Focused on immunity, Zhang et al. (2020) constructed the first TNF family-based model for predicting outcomes of LUAD patients, Li et al. (2017) developed and validated an individualized immune prognostic signature in early-stage non-squamous NSCLC. The gene discussed is TNF; the disease is non-small cell lung carcinoma.